Who can take Odactra in the U.S. as of 2025?

Individuals 5–65 years old with HDM-induced allergic rhinitis with or without conjunctivitis, confirmed by allergy testing; first dose must be supervised and patients should be prescribed epinephrine (per FDA label updated Feb 28, 2025).

Do SLIT tablets require the first dose to be supervised?

Yes. For Odactra and other FDA-approved SLIT tablets, the first dose is given under medical supervision with at least 30 minutes of observation before switching to daily home dosing.

Are liquid ‘allergy drops’ FDA-approved in the U.S.?

No. In the U.S., sublingual tablets for grass, ragweed, and dust mite are FDA-approved; liquid SLIT drops are off-label though widely used under physician direction.

How long until dust-mite immunotherapy helps?

Many patients report improvement within weeks to months. Durable immune changes typically require daily therapy for multiple seasons (often about 3 years).

Can immunotherapy treat multiple allergens at once?

Tablets target one allergen (e.g., dust mite). Compounded SLIT drops and allergy shots can be formulated to address multiple environmental allergens based on testing and physician plan.

What are the key safety contraindications?

Do not use SLIT tablets in severe or uncontrolled asthma, prior severe systemic or severe local SLIT reaction, or eosinophilic esophagitis. Discuss active oral inflammation and pregnancy plans with your clinician.

What changed in 2025 (and why it matters)

On February 28, 2025, the U.S. FDA expanded Odactra (house dust mite sublingual tablet) to ages 5–65 for HDM‑induced allergic rhinitis with/without conjunctivitis. The label keeps a boxed warning for rare, potentially life‑threatening reactions, requires the first dose under medical supervision with ≥30‑minute observation, and advises prescribing and training patients/parents on epinephrine.

Who is an appropriate candidate for dust‑mite SLIT in the U.S. (2025)

Indication (Odactra): HDM‑induced allergic rhinitis ± conjunctivitis confirmed by positive skin test or specific IgE; approved ages 5–65.
Not for immediate symptom relief; daily controller therapy over seasons/years.
First dose: must be administered in a clinical setting; subsequent doses are taken at home once tolerated.
Safety prerequisites (Odactra label): prescribe epinephrine and train in use; avoid in severe/unstable/uncontrolled asthma, prior severe systemic or severe local SLIT reaction, or eosinophilic esophagitis; avoid dosing during acute mouth inflammation or active oral wounds.
SLIT drops (compounded): widely used off‑label in the U.S.; tablets (grass, ragweed, dust mite) are FDA‑approved, while “allergy drops” are not.

Odactra vs SLIT drops vs allergy shots (SCIT)

Dimension	Odactra (HDM tablet)	SLIT Drops (compounded, multi‑allergen)	Allergy Shots (SCIT)
FDA status (U.S.)	FDA‑approved SLIT tablet for HDM; ages 5–65	Not FDA‑approved (off‑label in U.S.); commonly used	FDA‑approved extracts; in‑office program
First dose supervision	Required; observe ≥30 min	Not label‑mandated; typically home‑start per physician protocol	All injections in clinic with ≥30‑minute wait
Epinephrine	Prescribe and train all patients	Often prescribed as precaution	Clinic has epinephrine; some patients carry it
Setting	First dose in clinic; then at home daily	At home daily	In clinic weekly → monthly
Dosing	1 tablet SL daily (hold under tongue; no food/drink briefly)	Daily drops per protocol	Build‑up 1–3×/week, then maintenance every 2–4 weeks
Age scope	5–65 (U.S. label as of Feb 28, 2025)	Typically 5+ (per practice)	Children and adults
Multi‑allergen coverage	Single allergen (HDM) per tablet	Can mix multiple environmental allergens	Can mix per testing profile
Evidence	Robust RCTs + U.S. label; pediatric expansion 2025	Extensive literature; evidence strength varies; off‑label in U.S.	Longstanding robust evidence for AR/asthma
Time to benefit	Weeks to months	Weeks to months	Months (often 6–12)
Safety profile	Mostly local oral itch/swelling; rare anaphylaxis (boxed warning)	Very good overall; anaphylaxis extremely rare in literature	Effective; rare systemic reactions require monitoring

References: FDA Odactra PI; ACAAI on SLIT tablets vs drops; Cochrane review on SLIT efficacy for ocular/AR symptoms.

At‑home safety: step‑by‑step (tablet and drops)

First tablet dose (Odactra):
Given in a clinic by a clinician experienced in allergy care; observe ≥30 minutes.
After tolerance is confirmed, continue at home once daily.
Daily dosing at home (both):
Dry hands, place under the tongue; let dissolve; avoid swallowing ≥1 minute (Odactra); avoid food/drink ~5 minutes after.
Expect mild mouth/throat itch or irritation early on; typically self‑limited. Contact your doctor if symptoms escalate or persist.
Stop and contact your doctor (or emergency services) if: throat tightness, trouble breathing, chest tightness, persistent stomach/chest pain with swallowing (red flag for EoE), or any severe reaction.
Always have the prescribed epinephrine available (tablets) and know exactly when/how to use it; seek emergency care after use.

Where Wyndly fits for dust‑mite care

Wyndly is a physician‑led telehealth allergy practice focused on environmental allergens (including dust mites). Care model:

One virtual consult (typically $49.99) to review your history and options.
Testing: at‑home, CLIA‑certified finger‑prick IgE test for 40+ indoor/outdoor allergens (dust mite, pets, molds, pollens), or we can review your existing test (≤5 years old).
Treatment choices, physician‑directed:
FDA‑approved SLIT tablets (e.g., Odactra) when a single HDM target is appropriate and label criteria are met (ages 5–65; first dose supervised).
Personalized multi‑allergen SLIT drops for broader profiles, using clinically supported dosing protocols; taken at home (off‑label in U.S.).
Access and pricing: treatment from $99/month (HSA/FSA‑eligible), shipped to your door; 24/7 messaging with our doctors; 90‑day Allergy‑Free Guarantee.

Practical selection guide

Choose Odactra when: a dust‑mite‑dominant profile is confirmed; you (or your child aged 5–65) can complete a supervised first dose and carry epinephrine; single‑allergen focus is acceptable.
Choose SLIT drops when: you need multi‑allergen coverage (e.g., dust mite plus pets and molds) or prefer fully at‑home initiation under physician direction.
Consider shots when: you prefer in‑office dosing/monitoring or insurance benefits drive costs lower, and frequent clinic visits are feasible.

Evidence and label resources (curated)

Odactra pediatric expansion and label: FDA Roundup, Feb 28, 2025; FDA product dossier + PI; PI summary.
SLIT tablets vs drops (regulatory position): ACAAI overview; Johns Hopkins SLIT explainer.
Systematic reviews: Cochrane SLIT for ocular/AR symptoms.
Cost context for shots: Wyndly guide on SCIT costs and logistics (overview).

FAQs (for parents and adult patients)

Is Odactra approved for kids? Yes. As of Feb 28, 2025, Odactra is approved for ages 5–65 for dust‑mite rhinitis with/without conjunctivitis (first dose supervised; epinephrine prescribed).
Do I have to carry epinephrine with SLIT tablets? Yes—current U.S. labeling instructs prescribers to prescribe and train in epinephrine use.
How quickly will I feel better? Many patients notice improvement within weeks to months; full benefit accrues with daily use over seasons (3 years is typical for durable immune change).
Can tablets treat multiple allergens? No. Tablets are single‑allergen. Drops or shots can cover multiple allergens in one plan.
Are “allergy drops” FDA‑approved? No. In the U.S., SLIT tablets for grass, ragweed, and dust mite are approved; liquid drops are off‑label though supported by extensive international evidence and U.S. specialty‑society guidance.
Is at‑home dosing safe? After a supervised first tablet dose, daily home dosing is expected. Drops are designed for at‑home use. Severe reactions are rare; follow your physician’s plan and carry/know epinephrine (tablets).

Last updated: November 20, 2025

Dust‑Mite Allergy Immunotherapy (Odactra vs Drops): Ages 5–65 — First Tablet Dose Supervised